TERAZOSIN HYDROCHLORIDE - Generic Drug Details

✉ Email this page to a colleague

What are the generic sources for terazosin hydrochloride and what is the scope of patent protection?

Terazosin hydrochloride is the generic ingredient in three branded drugs marketed by Abbott, Apnar Pharma Lp, Bionpharma, Heritage Pharma Avet, Hikma, Jubilant Cadista, Norvium Bioscience, Ranbaxy Labs Ltd, Novitium Pharma, Chartwell Rx, Ivax Sub Teva Pharms, Sandoz, and Teva, and is included in fifteen NDAs. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

There are sixteen drug master file entries for terazosin hydrochloride. Twenty-one suppliers are listed for this compound.

Summary for TERAZOSIN HYDROCHLORIDE

US Patents:	1
Tradenames:	3
Applicants:	13
NDAs:	15
Drug Master File Entries:	16
Finished Product Suppliers / Packagers:	21
Raw Ingredient (Bulk) Api Vendors:	85
Clinical Trials:	24
Patent Applications:	2,326
What excipients (inactive ingredients) are in TERAZOSIN HYDROCHLORIDE?	TERAZOSIN HYDROCHLORIDE excipients list
DailyMed Link:	TERAZOSIN HYDROCHLORIDE at DailyMed

Recent Clinical Trials for TERAZOSIN HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Università Foro Italico Roma	Phase 4
CNR Pisa	Phase 4
I.R.C.C.S. Fondazione Santa Lucia	Phase 4

See all TERAZOSIN HYDROCHLORIDE clinical trials

Pharmacology for TERAZOSIN HYDROCHLORIDE

Drug Class	alpha-Adrenergic Blocker
Mechanism of Action	Adrenergic alpha-Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for TERAZOSIN HYDROCHLORIDE

G04CA	Alpha-adrenoreceptor antagonists
G04C	DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY
G04	UROLOGICALS
G	Genito-urinary system and sex hormones

US Patents and Regulatory Information for TERAZOSIN HYDROCHLORIDE

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novitium Pharma	TEZRULY	terazosin hydrochloride	SOLUTION;ORAL	218139-001	Jul 29, 2024		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
Teva	TERAZOSIN HYDROCHLORIDE	terazosin hydrochloride	TABLET;ORAL	074446-004	May 18, 2000		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Ivax Sub Teva Pharms	TERAZOSIN HYDROCHLORIDE	terazosin hydrochloride	TABLET;ORAL	074530-002	Apr 21, 2000		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Jubilant Cadista	TERAZOSIN HYDROCHLORIDE	terazosin hydrochloride	CAPSULE;ORAL	075317-004	Dec 20, 2004	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for TERAZOSIN HYDROCHLORIDE

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbott	HYTRIN	terazosin hydrochloride	CAPSULE;ORAL	020347-002	Dec 14, 1994	⤷ Sign Up	⤷ Sign Up
Abbott	HYTRIN	terazosin hydrochloride	TABLET;ORAL	019057-001	Aug 7, 1987	⤷ Sign Up	⤷ Sign Up
Abbott	HYTRIN	terazosin hydrochloride	TABLET;ORAL	019057-001	Aug 7, 1987	⤷ Sign Up	⤷ Sign Up
Abbott	HYTRIN	terazosin hydrochloride	CAPSULE;ORAL	020347-004	Dec 14, 1994	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.